ENOV — Enovis Corporation

Summary of Enovis Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Results: Revenue of $576 million, up 3% year-over-year (2% organic growth).
• Full Year 2025 Results: Total sales of $2.2 billion, representing 7% reported growth (6% organic growth).
• Adjusted EBITDA Margin: Held steady at 17.9% for the year, with adjusted earnings per share at $3.30, a 16% increase.
• Free Cash Flow: Returned to positive at $20 million, with a conversion rate of 10%.
• Goodwill Impairment: Recorded a noncash impairment of $501 million, which does not affect liquidity or future operations.

2. Strategic Updates and Business Highlights

• Key Priorities: Focus on commercial execution, operational excellence, and financial discipline under the "One Enovis" initiative.
• Segment Performance:
  • Recon: Achieved 8% organic growth, with strong performance in U.S. extremities and international markets.
  • Prevention and Recovery (P&R): Grew 4% organically, driven by bracing and BoneStim products.
• Innovation Pipeline: Significant product launches planned, including Arvis, with a flexible business model to drive implant utilization.
• Operational Improvements: Adjusted gross margins improved to 61%, driven by favorable product mix and productivity gains.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $2.31 billion and $2.37 billion, with mid-single-digit organic growth (4% to 6%).
• Adjusted EBITDA: Forecasted in the range of $425 million to $435 million, with a targeted margin improvement of 50 basis points.
• Free Cash Flow Conversion: Anticipated to exceed 25% in 2026, with a long-term goal of 70% to 80%.

4. Bad News, Challenges, or Points of Concern

• Q4 Performance: Growth was impacted by 4 fewer selling days, which contributed to lower-than-expected results.
• Goodwill Impairment: The significant impairment raises concerns about market perception and valuation.
• Market Dynamics: Potential headwinds from tariffs, currency fluctuations, and competitive pressures in the orthopedic market.
• Execution Issues: Acknowledgment of missed execution opportunities in Q4, indicating a need for improvement in commercial operations.

5. Notable Q&A Insights

• Free Cash Flow Improvement: Management highlighted operational efficiencies and reduced integration costs as key drivers for expected cash flow improvements in 2026.
• Arvis Launch: Anticipated rollout in phases, with a focus on driving implant utilization through flexible business models.
• Market Growth Expectations: Management expressed confidence in sustaining above-market growth in Recon, particularly in extremities and hips.
• Portfolio Shaping: Discussion on ongoing efforts to rationalize the product portfolio, with potential divestitures of slower-growing products to enhance overall growth and margin profiles.

Overall, Enovis demonstrated resilience in 2025, with a strong focus on execution and innovation, although challenges remain in market dynamics and execution efficiency. The outlook for 2026 appears positive, with strategic initiatives aimed at driving growth and improving financial metrics.